TABLE 6.
Changes in phenotypic and genotypic resistance after levofloxacin-based and clarithromycin-based triple therapies
| Type of therapya (no. of patients) or type of resistance | No. (%) of patients with changes in resistanceb after treatment |
|||
|---|---|---|---|---|
| S → S | R → R | S → R | R → S | |
| Levo-based therapy (11) | ||||
| Genotypic resistance to Levo | 7 (63.6) | 3 (27.3) | 1 (9.1) | 0 |
| Phenotypic resistance to Levo | 6 (54.5) | 2 (18.2) | 3 (27.3) | 0 |
| Clari-based therapy (9) | ||||
| Genotypic resistance to Claric | 0 | 4 (50) | 4 (50) | 0 |
| Phenotypic resistance to Clari | 2 (22.2) | 3 (33.3) | 4 (44.4) | 0 |
a
Levo, levofloxacin; Clari, clarithromycin.
b
S, susceptible; R, resistant; S → S, susceptible before and after triple therapy; R → R, resistant before and after triple therapy; S → R, susceptible before therapy and resistant after therapy; R → S, resistant before therapy and susceptible after therapy.
c
Genotyping for 23S rRNA was not available for one strain.